Theresa Mullin, Ph.D. and Director of FDA’s Office of Strategic Programs in the Center for Drug Evaluation and Research recently posted a blog on FDA Voice updating about the progress that has been made in the effort to listen and capture patient perspectives on the impact of their conditions on their day to day lives. On September 27th, the FDA held the 20th Patient Focused Drug Development (PFDD) meeting — a milestone meeting in the important work of listening to the patient. Patient perspective is valuable information in drug development and is a priority for FDA, healthcare providers and industry. Hearing from the patient community, their families and caregivers is important knowledge that will allow all to do their jobs even better in drug development, in reviews and in making decisions. Take a look at the Voice of the Patient Reports for an in-depth look at how disease impacts daily lives. It is a very important perspective to understand.
Obstacles Facing Biosimilars
Still in its infancy in the U.S., the industry faces some growing pains.
Life Science Accelerated
Our experts are dedicated to expediting life science product development regulatory pathways.